FDA approves prostate cancer drug delivery system

May 8, 2008

The FDA has approved Mixject, a new delivery system for triptorelin pamoate (Trelstar), a palliative treatment for advanced prostate cancer. Mixject combines triptorelin depot, 3.75 mg, and long-acting triptorelin, 11.25 mg, with new features that make preparation, administration, and disposal easier, according to Watson Pharmaceuticals, the manufactuer of triptorelin.

The FDA has approved Mixject, a new delivery system for triptorelin pamoate (Trelstar), a palliative treatment for advanced prostate cancer. Mixject combines triptorelin depot, 3.75 mg, and long-acting triptorelin, 11.25 mg, with new features that make preparation, administration, and disposal easier, according to Watson Pharmaceuticals, the manufactuer of triptorelin.

These new features include a smaller, 21-gauge needle for improved patient comfort, reconstitution without the use of a needle, and a shield covering the needle both before and after drug administration. The system is specifically designed to encourage compliance with OSHA regulations within the medical community.